{"gene":"LXN","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2005,"finding":"Crystal structure of human latexin (LXN) in complex with human carboxypeptidase A4 (hCPA4) revealed that LXN consists of two topologically equivalent subdomains structurally reminiscent of cystatins, each comprising an alpha-helix enveloped by a curved beta-sheet; the enzyme is bound at the interface of these subdomains. The complex occludes a large contact surface with relatively few contacts, explaining the nanomolar inhibition constant and the broad inhibitory spectrum across all vertebrate A/B metallocarboxypeptidases. Modeling studies explained why N/E subfamily MCPs and invertebrate A/B MCPs are not inhibited, due to differences in loop segments shaping the active-site access funnel.","method":"X-ray crystallography of LXN–hCPA4 complex; structural modeling for non-inhibited MCPs","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution crystal structure with mechanistic modeling; foundational structural paper","pmids":["15738388"],"is_preprint":false},{"year":2000,"finding":"Human LXN encodes a 222-amino-acid protein with 84% sequence identity to rat and mouse latexin. Northern blot analysis demonstrated broad expression in 15 of 16 tissues examined (absent in peripheral blood leukocytes), with highest levels in heart, prostate, ovary, kidney, pancreas, and colon. The LXN gene spans ~5.9 kb, contains at least 6 exons, and maps to chromosome 3q25-q26.2.","method":"cDNA cloning from human fetal brain library; Northern blot analysis; genomic mapping","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct cloning and expression profiling; single lab, multiple methods","pmids":["11455960"],"is_preprint":false},{"year":2013,"finding":"In human prostate epithelial cells, LXN localizes to the nucleus (distinct from RARRES1, which localizes to the endoplasmic reticulum). siRNA-mediated knockdown of LXN enhanced colony-forming ability (stem cell properties) and increased invasive capacity of primary prostate cultures. Inhibition of LXN fully rescued the anti-invasive effect induced by all-trans retinoic acid (atRA), establishing LXN as a downstream mediator of atRA's anti-invasion activity. LXN expression was co-ordinately repressed by DNA methylation in prostate cancer cell lines.","method":"siRNA knockdown; colony formation assay; invasion assay; subcellular localization by immunofluorescence; bisulfite methylation analysis","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with multiple orthogonal phenotypic readouts and localization data; single lab","pmids":["23588494"],"is_preprint":false},{"year":2011,"finding":"Overexpression of LXN in LXN-negative gastric cancer cells (MGC803) inhibited colony formation and suppressed tumor growth in nude mice, while antisense-mediated knockdown in LXN-positive BGC823 cells enhanced tumor growth and colony formation. LXN overexpression differentially regulated tumor-related genes including Maspin, WFDC1, SLPI, S100P, and PDGFRB. CpG hypermethylation of the LXN promoter correlated with silenced LXN expression in cancer cell lines.","method":"Stable transfection (overexpression and antisense knockdown); colony formation assay; nude mouse xenograft; microarray gene expression; bisulfite sequencing","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with in vitro and in vivo readouts; single lab","pmids":["21466706"],"is_preprint":false},{"year":2012,"finding":"Retrovirus-mediated overexpression of LXN in A20 mouse lymphoma cells inhibited in vitro growth ~16-fold and in vivo tumor volume ~2-fold. LXN-induced growth inhibition was associated with increased apoptosis and downregulation of anti-apoptotic genes Bcl-2 and Pim-2. Importantly, this tumor-suppressive mechanism was not dependent on LXN's canonical carboxypeptidase inhibitor activity.","method":"Retroviral overexpression; in vitro proliferation assay; mouse xenograft; RT-PCR for Bcl-2 and Pim-2; apoptosis assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function in vitro and in vivo with defined molecular readouts; single lab","pmids":["23028717"],"is_preprint":false},{"year":2012,"finding":"Proteomic analysis of Sca-1+ bone marrow cells from LXN-knockout mice demonstrated that latexin ablation reduced the abundance of multiple proteins involved in HSC niche interaction, including N-cadherin, Tie2, and Roundabout 4. LXN was found to co-localize with these niche molecules in hematopoietic stem/progenitor cells. LXN-deficient KSL cells showed enhanced self-renewal in methylcellulose colony assays, and LXN knockout increased KSL cell numbers in vivo.","method":"LXN-knockout mouse model; proteomics of Sca-1+ cells; immunofluorescence co-localization; methylcellulose colony assay; flow cytometry","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 — KO model with proteomics and functional colony assay; single lab","pmids":["21567403"],"is_preprint":false},{"year":2013,"finding":"Exogenous LXN expression in melanoma cell lines significantly inhibited tumor cell proliferation and correlated with reduced expression of stem cell transcription factors OCT4, NANOG, SOX2, KLF4, and MYCN, suggesting LXN suppresses the stem cell-like properties of melanoma cells. The LXN CpG island promoter was hypermethylated in melanoma cell lines and tumors; 5-aza-2'-deoxycytidine treatment restored LXN expression.","method":"Exogenous LXN expression; proliferation assay; RT-PCR/Western blot for stem cell factors; bisulfite sequencing; demethylation drug treatment","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — gain-of-function with molecular readouts; single lab","pmids":["23364479"],"is_preprint":false},{"year":2014,"finding":"LXN overexpression in hepatocellular carcinoma cells (SK-hep-1) promoted G0/G1 cell cycle arrest, while LXN silencing in YY-8103 cells promoted transition from G0/G1 to S phase. These effects were associated with differential expression of CDK inhibitors p21Cip1, p27Kip1, and p15INK4B, as well as cyclin D1 and cyclin E.","method":"LXN overexpression and shRNA knockdown; flow cytometry cell cycle analysis; Western blot for cell cycle regulators; colony formation; nude mouse xenograft","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with defined cell cycle molecular mechanism; single lab","pmids":["24399246"],"is_preprint":false},{"year":2014,"finding":"LXN protein treatment of CD133+ MiaPaCa-2 pancreatic cancer stem-like cells increased apoptosis and inhibited proliferation in a dose-dependent manner, associated with downregulation of Bcl-2 and c-myc and upregulation of Bax.","method":"Exogenous LXN protein treatment; CCK-8 proliferation assay; flow cytometry apoptosis assay; Western blot for Bcl-2, Bax, c-myc","journal":"World journal of surgical oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct protein treatment with defined apoptotic molecular mechanism; single lab","pmids":["25551472"],"is_preprint":false},{"year":2017,"finding":"LXN knockdown conferred docetaxel resistance to prostate cancer cells in vitro and in vivo, while LXN overexpression sensitized cells to docetaxel. Bone stromal cells decreased LXN expression through promoter methylation, inducing chemoresistance in co-cultured prostate cancer cells. In a mouse model, prostate cancer cells developed docetaxel resistance specifically in the bone microenvironment, coinciding with decreased LXN expression compared to the soft tissue microenvironment.","method":"siRNA knockdown; LXN overexpression; docetaxel resistance assays in vitro and in vivo; mouse xenograft; co-culture with bone stromal cells; bisulfite methylation analysis","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal gain/loss-of-function with in vitro and in vivo validation; single lab","pmids":["28087740"],"is_preprint":false},{"year":2019,"finding":"LXN protein is both cytosolic and secreted by normal prostate luminal cells. LXN overexpression in the luminal prostate cancer line LNCaP reduced plating efficiency. Transcriptome analysis showed LXN overexpression had significant indirect effects on genes involved in retinoid metabolism and IFN-associated inflammatory responses, without direct transcriptional effects, suggesting a post-transcriptional or signaling mechanism.","method":"LXN overexpression; colony/plating efficiency assay; transcriptome analysis (RNA-seq); Western blot; conditioned medium analysis for secretion","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — secretion demonstrated, transcriptome analysis reveals indirect pathway effects; single lab","pmids":["30914656"],"is_preprint":false},{"year":2020,"finding":"LXN was identified as a suppressor of colitis. Proteomics revealed LXN physically interacts with HECTD1 (an E3 ubiquitin ligase) and ribosomal protein subunit Rps3, forming a functional complex. LXN expression promotes IκBα accumulation in intestinal epithelial cells; LXN knockdown enhances the HECTD1-Rps3 interaction, leading to ubiquitination and degradation of IκBα, and thereby activating NF-κB-driven inflammatory response. LXN deficiency aggravated DSS-induced colitis in mice.","method":"Proteomics/co-immunoprecipitation to identify LXN–HECTD1–Rps3 complex; Western blot for IκBα ubiquitination; LXN knockout mouse model (DSS colitis); ectopic LXN expression","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 — complex identified by proteomics and Co-IP, ubiquitination mechanism established, validated in KO mouse model; multiple orthogonal methods","pmids":["32555320"],"is_preprint":false},{"year":2021,"finding":"LXN interacts with Filamin A (FLNA) and regulates FLNA proteolytic cleavage and nuclear translocation in vascular endothelial cells. Laminar shear stress (LSS) reduces LXN expression in ECs; LXN knockdown recapitulates LSS-induced morphological changes and F-actin remodeling. LXN-/- and ApoE-/-LXN-/- double-knockout mice showed improved vascular permeability, vasodilation, and reduced atherosclerosis, establishing LXN as a regulator of endothelial morphology and vascular homeostasis.","method":"Co-immunoprecipitation (LXN–FLNA interaction); siRNA knockdown; F-actin imaging; LXN-/- and double-KO mouse models; vascular permeability and vasodilation assays; atherosclerosis assessment","journal":"Journal of cellular and molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — Co-IP interaction, KD phenotype with imaging, and in vivo KO model with multiple vascular endpoints; multiple orthogonal methods","pmids":["34085389"],"is_preprint":false},{"year":2022,"finding":"LXN deficiency in macrophages promotes M2 polarization and upregulates PD-L2 expression (but not PD-L1), inhibiting T cell function in the tumor microenvironment. Mechanistically, LXN inhibits STAT3 transcriptional activity by targeting inhibition of JAK1 in macrophages. Adoptive transfer of wild-type macrophages rescued T cell function in LXN-deficient mice. Targeted inhibition of PD-L2 ameliorated cancer growth in LXN-deficient mice.","method":"LXN-knockout mouse model; subcutaneous tumor and AOM/DSS colorectal cancer models; flow cytometry for immune cell populations and polarization; co-culture macrophage-T cell systems; Western blot for JAK1/STAT3; adoptive macrophage transfer; PD-L2 inhibition","journal":"Cell death discovery","confidence":"High","confidence_rationale":"Tier 2 — KO mouse model with multiple tumor models, mechanistic pathway (JAK1/STAT3), adoptive transfer rescue; multiple orthogonal methods","pmids":["36323670"],"is_preprint":false},{"year":2024,"finding":"LXN colocalizes with Lgr5+ intestinal stem cells (ISCs) in crypts. LXN deletion upregulates Lgr5 expression and enhances ISC proliferation, promoting intestinal organoid development. Mechanistically, LXN deficiency activates both the YAP and Wnt signaling pathways in ISCs, accelerating normal intestinal growth and regeneration post-injury.","method":"LXN-knockout mouse model; immunofluorescence co-localization with Lgr5; intestinal organoid culture; Western blot for YAP and Wnt pathway components; DSS-induced injury model","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 — KO model with organoid functional assay and pathway analysis; single lab","pmids":["39208900"],"is_preprint":false},{"year":2024,"finding":"LXN is secreted by macrophages via exosomes. LXN-enriched macrophage-derived exosomes inhibit CD4+ T cell differentiation into Treg cells both in vitro and in vivo, enhancing tumor immune surveillance. Biomimetic nanoparticles loaded with LXN protein (MØ@LXN-NPS) recapitulated this Treg-inhibitory and anti-tumor activity.","method":"Macrophage-T cell co-culture system; exosome isolation and characterization; flow cytometry for Treg differentiation; in vivo tumor models; biomimetic nanoparticle engineering","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 — exosomal secretion established, functional Treg inhibition shown in vitro and in vivo; single lab","pmids":["39694381"],"is_preprint":false},{"year":2024,"finding":"LXN knockdown in endometrial stromal cells reduced their migratory capacity while promoting cell viability, indicating LXN positively regulates migration and negatively regulates proliferation in this cell type.","method":"LXN knockdown; Transwell migration assay; MTT viability assay","journal":"Genes","confidence":"Low","confidence_rationale":"Tier 3 — single lab, two functional assays without defined pathway mechanism","pmids":["39202445"],"is_preprint":false},{"year":2025,"finding":"In renal tubular epithelial cells (RTECs), oxalate-induced oxidative stress activates the LXN/Rps3/p53 signaling pathway, promoting premature cellular senescence and SASP factor secretion, which in turn drives M1-like macrophage polarization and increased calcium oxalate crystal deposition. siRNA knockdown of LXN, or AAV-shLXN in a rat kidney stone model, reduced RTEC senescence, decreased SASP, reversed M1 macrophage polarization, and diminished intrarenal CaOx crystal deposition.","method":"siRNA knockdown of LXN; AAV-shLXN in rat model; SA-β-gal senescence staining; SASP cytokine measurement; macrophage co-culture; immunohistochemistry; Von Kossa staining","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — pathway established with siRNA and in vivo AAV knockdown with multiple mechanistic readouts; single lab","pmids":["41112268"],"is_preprint":false},{"year":2026,"finding":"LXN knockdown in mice (AAV9-shLXN) reduced CCl4-induced liver injury and suppressed hepatic stellate cell (HSC) activation, inhibiting α-SMA and collagen I expression. LXN expression showed a substantial positive correlation with THBS2 (thrombospondin-2), and LXN knockdown downregulated THBS2, suggesting LXN promotes liver fibrosis via a LXN-THBS2 signaling axis that drives HSC activation.","method":"AAV9-mediated LXN knockdown in mouse CCl4 liver fibrosis model; siLXN in LX-2 cells; qPCR; Western blot; immunohistochemistry; immunofluorescence","journal":"Frontiers in bioscience (Landmark edition)","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro KD with defined molecular axis; single lab, correlation-supported mechanism","pmids":["41761978"],"is_preprint":false},{"year":2024,"finding":"In smooth muscle cells (SMCs), LXN deficiency significantly attenuated SMC proliferation and migration by inhibiting PDGF receptor expression. In macrophages, LXN deficiency inhibited MCP-1-induced macrophage migration by suppressing ERK phosphorylation. Global, SMC-specific, and myeloid-specific LXN knockout (but not endothelial-specific KO) markedly prevented neointimal hyperplasia after carotid artery ligation in mice.","method":"Cell-type-specific LXN KO mouse models (global, SMC-specific, EC-specific, myeloid-specific); carotid artery ligation model; Western blot for PDGF receptors and ERK phosphorylation; immunofluorescence; proliferation and migration assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific KO models with defined molecular mechanisms; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2024.10.03.616555"],"is_preprint":true},{"year":2018,"finding":"LXN acts endogenously in hematopoietic stem cells (HSCs) to negatively regulate their population size by enhancing apoptosis and decreasing self-renewal. LXN interacts with ribosomal protein Rps3 and inhibits its nuclear translocation, sensitizing hematopoietic cells to radiation-induced cell death. LXN inactivation downregulates thrombospondin 1 (Thbs1), connecting the LXN-Rps3 axis to downstream transcriptional effects.","method":"LXN knockout mouse model; repopulation assays; apoptosis assays; co-immunoprecipitation (LXN-Rps3); nuclear fractionation for Rps3 localization; radiation sensitivity assays (review summarizing primary experimental data)","journal":"Current opinion in hematology","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing primary experimental findings (KO model, Co-IP, nuclear translocation) from the field; replicated across related studies","pmids":["29608488"],"is_preprint":false}],"current_model":"LXN (latexin) is a secreted/cytosolic vertebrate metallocarboxypeptidase inhibitor whose crystal structure reveals it binds hCPA4 at the interface of two cystatin-like subdomains with nanomolar affinity; beyond this canonical enzymatic inhibitor role, LXN functions as a negative regulator of hematopoietic stem cell self-renewal and a tumor suppressor by forming a complex with HECTD1 and Rps3 to stabilize IκBα and suppress NF-κB signaling, inhibiting JAK1/STAT3 to prevent macrophage M2 polarization and PD-L2 upregulation, interacting with Filamin A to maintain endothelial cytoskeletal homeostasis, activating YAP/Wnt signaling in intestinal stem cells, driving a LXN/Rps3/p53 senescence axis in renal epithelial cells, and regulating SMC proliferation via PDGF receptor expression and macrophage migration via ERK phosphorylation."},"narrative":{"teleology":[{"year":2000,"claim":"Cloning of human LXN established it as a broadly expressed gene mapping to 3q25-q26.2, setting the stage for functional studies beyond the original rat brain context.","evidence":"cDNA cloning from human fetal brain library; Northern blot across 16 tissues; genomic mapping","pmids":["11455960"],"confidence":"Medium","gaps":["No functional assay performed in this study","Protein-level expression across tissues not assessed"]},{"year":2005,"claim":"Determination of the LXN–hCPA4 crystal structure resolved the molecular basis of metallocarboxypeptidase inhibition, revealing two cystatin-like subdomains that clamp the enzyme's active-site funnel with nanomolar affinity and explaining why invertebrate and N/E-subfamily MCPs escape inhibition.","evidence":"X-ray crystallography of LXN–hCPA4 complex; structural modeling of non-inhibited MCPs","pmids":["15738388"],"confidence":"High","gaps":["No mutagenesis to validate key contact residues","Kinetic parameters for inhibition of individual MCP family members not systematically measured"]},{"year":2011,"claim":"Reciprocal gain- and loss-of-function experiments in gastric cancer demonstrated that LXN acts as a tumor suppressor whose promoter is silenced by CpG methylation, linking epigenetic regulation to its growth-inhibitory role.","evidence":"Stable overexpression and antisense knockdown in gastric cancer cells; nude mouse xenograft; bisulfite sequencing","pmids":["21466706"],"confidence":"Medium","gaps":["Downstream targets (Maspin, PDGFRB, etc.) identified by microarray but not validated by loss-of-function","Methylation-growth relationship is correlative, no demethylation rescue in vivo"]},{"year":2012,"claim":"Studies in hematopoietic stem cells and lymphoma cells established that LXN restricts HSC self-renewal and induces apoptosis through a mechanism independent of its carboxypeptidase-inhibitory activity, broadening its functional repertoire beyond enzyme inhibition.","evidence":"LXN-KO mouse HSC colony assays and proteomics; retroviral LXN overexpression in A20 lymphoma cells with apoptosis and xenograft readouts","pmids":["21567403","23028717"],"confidence":"Medium","gaps":["The carboxypeptidase-independent mechanism was not molecularly defined at this stage","Downstream apoptotic targets (Bcl-2, Pim-2) not validated by rescue experiments"]},{"year":2013,"claim":"Nuclear localization of LXN in prostate epithelial cells and its role as a mediator of retinoic acid–induced invasion suppression revealed a compartment-specific tumor-suppressive function distinct from its cytosolic enzymatic role.","evidence":"siRNA knockdown; invasion and colony-formation assays; immunofluorescence localization; bisulfite methylation analysis in prostate cells","pmids":["23588494"],"confidence":"Medium","gaps":["Nuclear binding partners not identified","Mechanism linking nuclear LXN to retinoic acid signaling pathway not defined"]},{"year":2014,"claim":"Identification of LXN-regulated cell cycle arrest via CDK inhibitors (p21, p27, p15) and cyclin D1/E in hepatocellular carcinoma provided a concrete proliferative checkpoint mechanism for its tumor-suppressive activity.","evidence":"LXN overexpression and shRNA knockdown in HCC lines; flow cytometry cell cycle analysis; Western blot for CDK inhibitors","pmids":["24399246"],"confidence":"Medium","gaps":["Direct versus indirect regulation of CDK inhibitors not distinguished","No epistasis experiment to confirm CDK inhibitors are required for LXN-mediated arrest"]},{"year":2018,"claim":"The discovery that LXN binds Rps3 and inhibits its nuclear translocation provided the first defined signaling partner for LXN's carboxypeptidase-independent functions in HSC regulation and radiation sensitivity.","evidence":"Co-immunoprecipitation of LXN–Rps3; nuclear fractionation; LXN-KO mouse repopulation and radiation sensitivity assays","pmids":["29608488"],"confidence":"Medium","gaps":["Primary data cited from review; structural basis of LXN–Rps3 interaction unknown","Downstream transcriptional targets of nuclear Rps3 in HSCs not comprehensively defined"]},{"year":2020,"claim":"Identification of the LXN–HECTD1–Rps3 complex and its role in stabilizing IκBα to suppress NF-κB provided a defined ubiquitin-dependent mechanism through which LXN restrains intestinal inflammation.","evidence":"Proteomics and Co-IP for LXN–HECTD1–Rps3 complex; IκBα ubiquitination assays; LXN-KO mouse DSS colitis model","pmids":["32555320"],"confidence":"High","gaps":["Whether LXN competes with Rps3 for HECTD1 binding or allosterically modulates the complex is unresolved","No structural model of the ternary complex"]},{"year":2021,"claim":"Discovery that LXN interacts with Filamin A and regulates its cleavage and nuclear translocation extended LXN's mechanistic scope to cytoskeletal and vascular homeostasis, with LXN deletion protecting against atherosclerosis.","evidence":"Co-IP of LXN–FLNA; siRNA knockdown with F-actin imaging; LXN−/− and ApoE−/−LXN−/− double-KO mice with vascular permeability, vasodilation, and atherosclerosis endpoints","pmids":["34085389"],"confidence":"High","gaps":["Binding domain on FLNA not mapped","Mechanism by which LXN regulates FLNA proteolytic cleavage not identified"]},{"year":2022,"claim":"Demonstration that LXN inhibits JAK1/STAT3 signaling in macrophages to prevent M2 polarization and PD-L2 upregulation established LXN as a checkpoint in anti-tumor immunity, rescued by adoptive transfer of WT macrophages.","evidence":"LXN-KO mouse tumor models; macrophage–T cell co-culture; Western blot for JAK1/STAT3; adoptive macrophage transfer; PD-L2 blockade","pmids":["36323670"],"confidence":"High","gaps":["Direct physical interaction between LXN and JAK1 not demonstrated","Mechanism of selective PD-L2 (not PD-L1) regulation unclear"]},{"year":2024,"claim":"Multiple 2024 studies revealed additional LXN functions: activation of YAP/Wnt in intestinal stem cells upon LXN loss, exosomal LXN secretion by macrophages that inhibits Treg differentiation, and context-dependent roles in endometrial stromal cell migration.","evidence":"LXN-KO mouse intestinal organoids with YAP/Wnt pathway analysis; exosome isolation from macrophages with Treg co-culture; LXN knockdown in endometrial stromal cells","pmids":["39208900","39694381","39202445"],"confidence":"Medium","gaps":["YAP and Wnt activation mechanism (direct target vs. indirect) not resolved","Exosomal LXN cargo sorting mechanism unknown","Endometrial migration finding lacks pathway-level mechanism"]},{"year":2025,"claim":"The LXN/Rps3/p53 axis was implicated in oxidative stress–induced cellular senescence in renal tubular cells, linking LXN to SASP-driven macrophage polarization and kidney stone pathogenesis.","evidence":"siRNA and AAV-shLXN knockdown in rat kidney stone model; SA-β-gal senescence staining; SASP cytokine measurement; macrophage co-culture","pmids":["41112268"],"confidence":"Medium","gaps":["How LXN activates p53 is not defined","Whether the Rps3 interaction mediates p53 stabilization or transcriptional activation is untested"]},{"year":null,"claim":"Key unresolved questions include the structural basis of LXN's interactions with Rps3, HECTD1, and FLNA; how a single protein integrates carboxypeptidase inhibition with NF-κB, JAK/STAT, YAP/Wnt, and p53 signaling; and whether these diverse functions are executed by distinct LXN pools (nuclear, cytosolic, secreted/exosomal).","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of LXN in complex with any non-MCP partner","Compartment-specific functions not systematically dissected with domain mutants","Relative contribution of carboxypeptidase-dependent vs -independent mechanisms to in vivo phenotypes untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,4,13]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,12]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[10,15]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,13,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,13,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,8,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,6,7,9]}],"complexes":["LXN-HECTD1-Rps3"],"partners":["CPA4","RPS3","HECTD1","FLNA"],"other_free_text":[]},"mechanistic_narrative":"Latexin (LXN) is a vertebrate-specific protein that functions both as a nanomolar-affinity inhibitor of A/B metallocarboxypeptidases and as a pleiotropic regulator of cell proliferation, apoptosis, and inflammatory signaling in diverse tissue contexts. Structurally, LXN comprises two cystatin-like subdomains that bind the active-site funnel of carboxypeptidase A4, occluding a large contact surface to achieve broad-spectrum inhibition of vertebrate metallocarboxypeptidases [PMID:15738388]. Independent of its carboxypeptidase-inhibitory activity, LXN negatively regulates hematopoietic stem cell self-renewal and promotes apoptosis through interaction with ribosomal protein Rps3 and inhibition of its nuclear translocation [PMID:29608488, PMID:23028717]; in intestinal epithelial cells, LXN forms a complex with the E3 ubiquitin ligase HECTD1 and Rps3 to stabilize IκBα and suppress NF-κB-driven inflammation [PMID:32555320], while in macrophages it restrains M2 polarization and PD-L2 expression by inhibiting JAK1/STAT3 signaling [PMID:36323670]. LXN is frequently silenced by promoter CpG hypermethylation across gastric, prostate, melanoma, and hepatocellular cancers, and its re-expression suppresses tumor growth, induces G0/G1 arrest, and sensitizes cancer cells to chemotherapy [PMID:21466706, PMID:24399246, PMID:28087740]."},"prefetch_data":{"uniprot":{"accession":"Q9BS40","full_name":"Latexin","aliases":["Endogenous carboxypeptidase inhibitor","ECI","Protein MUM","Tissue carboxypeptidase inhibitor","TCI"],"length_aa":222,"mass_kda":25.8,"function":"Hardly reversible, non-competitive, and potent inhibitor of CPA1, CPA2 and CPA4. May play a role in inflammation","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9BS40/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LXN","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LXN","total_profiled":1310},"omim":[{"mim_id":"609305","title":"LATEXIN; LXN","url":"https://www.omim.org/entry/609305"},{"mim_id":"607635","title":"CARBOXYPEPTIDASE A4; CPA4","url":"https://www.omim.org/entry/607635"},{"mim_id":"601573","title":"ENHANCER OF ZESTE 2 POLYCOMB REPRESSIVE COMPLEX 2 SUBUNIT; EZH2","url":"https://www.omim.org/entry/601573"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/LXN"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q9BS40","domains":[{"cath_id":"3.10.450.10","chopping":"9-93","consensus_level":"medium","plddt":97.0999,"start":9,"end":93},{"cath_id":"3.10.450.10","chopping":"101-215","consensus_level":"medium","plddt":97.5702,"start":101,"end":215}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BS40","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BS40-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BS40-F1-predicted_aligned_error_v6.png","plddt_mean":95.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LXN","jax_strain_url":"https://www.jax.org/strain/search?query=LXN"},"sequence":{"accession":"Q9BS40","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BS40.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BS40/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BS40"}},"corpus_meta":[{"pmid":"23588494","id":"PMC_23588494","title":"Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN.","date":"2013","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23588494","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36323670","id":"PMC_36323670","title":"Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36323670","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34085389","id":"PMC_34085389","title":"LXN deficiency regulates cytoskeleton remodelling by promoting proteolytic cleavage of Filamin A in vascular endothelial cells.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34085389","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36949500","id":"PMC_36949500","title":"Circ_0002715 promotes the development of osteoarthritis through regulating LXN by sponging miR-127-5p.","date":"2023","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/36949500","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38442573","id":"PMC_38442573","title":"Therapeutic potential of ADSC-EV-derived lncRNA DLEU2: A novel molecular pathway in alleviating sepsis-induced lung injury via the miR-106a-5p/LXN axis.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38442573","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39202445","id":"PMC_39202445","title":"Carboxypeptidase Inhibitor LXN Expression in Endometrial Tissue Is Menstrual Cycle Phase-Dependent and Is Upregulated in Endometriotic Lesions.","date":"2024","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/39202445","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41112268","id":"PMC_41112268","title":"Premature renal epithelial cell senescence promoted by LXN/Rps3/p53 signaling pathway activation increases calcium oxalate crystal deposition by altering macrophage polarization.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41112268","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39208900","id":"PMC_39208900","title":"Carboxypeptidase inhibitor Latexin (LXN) regulates intestinal organogenesis and intestinal remodeling involved in intestinal injury repair in mice.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39208900","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39694381","id":"PMC_39694381","title":"Latexin (LXN) enhances tumor immune surveillance in mice by inhibiting Treg cells through the macrophage exosome pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39694381","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41761978","id":"PMC_41761978","title":"LXN-THBS2 Signaling Axis Regulates Hepatic Stellate Cell Activation and Promotes the Development of Liver Fibrosis.","date":"2026","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/41761978","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.10.03.616555","title":"Latexin facilitates neointimal formation via promoting smooth muscle cell proliferation and macrophage migration","date":"2024-10-04","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.03.616555","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.06.24312838","title":"Divergent inflammatory and neurology-related plasma protein profiles in individuals with long COVID following primary and breakthrough SARS-CoV-2 infections","date":"2024-09-06","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.06.24312838","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.08.02.24310874","title":"Genetics of Cardiac Aging Implicate Organ-Specific Variation","date":"2024-08-06","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.02.24310874","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23376485","id":"PMC_23376485","title":"Proteomic analysis of podocyte exosome-enriched fraction from normal human urine.","date":"2013","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/23376485","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15738388","id":"PMC_15738388","title":"Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15738388","citation_count":85,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11455960","id":"PMC_11455960","title":"Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor.","date":"2000","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/11455960","citation_count":40,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30463901","id":"PMC_30463901","title":"BAP1 regulation of the key adaptor protein NCoR1 is critical for γ-globin gene repression.","date":"2018","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30463901","citation_count":32,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21466706","id":"PMC_21466706","title":"Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential.","date":"2011","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21466706","citation_count":30,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23364479","id":"PMC_23364479","title":"The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma.","date":"2013","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23364479","citation_count":29,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32555320","id":"PMC_32555320","title":"Latexin deficiency in mice up-regulates inflammation and aggravates colitis through HECTD1/Rps3/NF-κB pathway.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32555320","citation_count":27,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21567403","id":"PMC_21567403","title":"Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21567403","citation_count":23,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24399246","id":"PMC_24399246","title":"Latexin exhibits tumor suppressor potential in hepatocellular carcinoma.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24399246","citation_count":22,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29791485","id":"PMC_29791485","title":"Alterations in the brain interactome of the intrinsically disordered N-terminal domain of the cellular prion protein (PrPC) in Alzheimer's disease.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29791485","citation_count":21,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23028717","id":"PMC_23028717","title":"Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23028717","citation_count":19,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30914656","id":"PMC_30914656","title":"The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30914656","citation_count":18,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23712706","id":"PMC_23712706","title":"Clinical significance of CD146 and latexin during different stages of thyroid cancer.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23712706","citation_count":13,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28087740","id":"PMC_28087740","title":"Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28087740","citation_count":13,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26530530","id":"PMC_26530530","title":"Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26530530","citation_count":11,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25551472","id":"PMC_25551472","title":"Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells.","date":"2014","source":"World journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25551472","citation_count":10,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"39653747","id":"PMC_39653747","title":"The comprehensive SARS-CoV-2 'hijackome' knowledge base.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/39653747","citation_count":7,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29608488","id":"PMC_29608488","title":"Latexin and hematopoiesis.","date":"2018","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29608488","citation_count":6,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9340,"output_tokens":2173,"usd":0.030308},"stage2":{"model":"claude-opus-4-6","input_tokens":5466,"output_tokens":1991,"usd":0.115657},"total_usd":0.430715,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":20964,"output_tokens":6971,"usd":0.083728},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":9693,"output_tokens":3422,"usd":0.201022}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"LXN localizes to the nucleus of prostate epithelial cells (distinct from RARRES1 which is in the endoplasmic reticulum), and siRNA suppression of LXN enhances stem cell colony-forming ability and increases invasive capacity of primary prostate cultures, fully rescuing atRA-induced invasion inhibition.\",\n      \"method\": \"siRNA knockdown, cell imaging/subcellular fractionation, colony-forming assay, invasion assay\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct localization experiment with functional consequence; siRNA KD with specific phenotypic readouts, single lab\",\n      \"pmids\": [\"23588494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LXN physically interacts with Filamin A (FLNA) and regulates its proteolytic cleavage and nuclear translocation; LXN knockdown in endothelial cells causes F-actin remodelling and morphological changes, and LXN-/- mice show improved vascular permeability, vasodilation, and reduced atherosclerosis.\",\n      \"method\": \"Co-immunoprecipitation/interaction assay, siRNA knockdown, cell imaging, LXN-/- and ApoE-/-LXN-/- double-knockout mouse models\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal interaction demonstrated, KO mouse with defined vascular phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"34085389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LXN inhibits STAT3 transcriptional activity by targeting inhibition of JAK1 in macrophages; LXN deficiency enhances PD-L2 (not PD-L1) expression in macrophages, leading to T cell suppression in the tumor microenvironment, and promotes macrophage M2 polarization.\",\n      \"method\": \"LXN-deficient mouse models, adoptive macrophage transfer, targeted PD-L2 inhibition, mechanistic pathway analysis (JAK1/STAT3)\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic pathway placement with KO mice and adoptive transfer rescue, single lab\",\n      \"pmids\": [\"36323670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN deficiency in intestinal stem cells activates YAP and Wnt signaling pathways, upregulates Lgr5 expression, and promotes ISC proliferation and intestinal organoid development; LXN co-localizes with Lgr5 in intestinal crypts.\",\n      \"method\": \"LXN knockout mice, intestinal organoid culture, co-localization imaging, western blot/pathway analysis\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KO mouse with organoid functional readout and pathway placement, single lab\",\n      \"pmids\": [\"39208900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN in macrophages is secreted extracellularly via exosomes; LXN-enriched macrophage-derived exosomes inhibit CD4+ T cell differentiation into Treg cells in vitro and in vivo, thereby enhancing tumor immune surveillance.\",\n      \"method\": \"Macrophage-T cell co-culture system, exosome isolation and characterization, in vivo tumor models, biomimetic nanoparticle (MØ@LXN-NPS) loaded with LXN protein\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — exosome secretion pathway established with functional in vitro and in vivo readouts, single lab\",\n      \"pmids\": [\"39694381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LXN activates the LXN/Rps3/p53 signaling pathway in renal tubular epithelial cells under oxalate stress, promoting cellular senescence and SASP factor secretion, which drives M1-like macrophage polarization and increases calcium oxalate crystal deposition; LXN silencing reduces RTEC senescence and M1 macrophage polarization in vivo.\",\n      \"method\": \"siRNA knockdown, AAV-shLXN in vivo knockdown, SA-β-gal staining, SASP measurement, macrophage polarization assay, rat kidney stone model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement with siRNA and in vivo AAV knockdown, multiple functional readouts, single lab\",\n      \"pmids\": [\"41112268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LXN knockdown suppresses hepatic stellate cell activation, inhibits α-SMA and collagen I expression, and downregulates THBS2; LXN demonstrates a positive correlation with THBS2, suggesting an LXN-THBS2 signaling axis that promotes liver fibrosis progression.\",\n      \"method\": \"AAV9-mediated LXN knockdown in mouse liver fibrosis model (CCl4), siLXN in LX-2 cells, qPCR, western blot, immunohistochemistry\",\n      \"journal\": \"Frontiers in bioscience (Landmark edition)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — KD with phenotypic readout and correlative pathway placement, no direct mechanistic interaction demonstrated, single lab\",\n      \"pmids\": [\"41761978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SMC-specific LXN deficiency prevents neointimal hyperplasia by inhibiting SMC proliferation and migration via attenuation of PDGF receptor expression; myeloid-specific LXN deficiency inhibits MCP-1-induced macrophage migration through inhibition of ERK phosphorylation.\",\n      \"method\": \"Cell-type-specific KO mice (global, SMC-specific, endothelial-specific, myeloid-specific), carotid artery ligation model, western blot, immunofluorescence\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO mice with defined molecular mechanism (PDGF receptor, ERK phosphorylation), multiple genetic models, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN knockdown reduces migratory capacity of endometrial stromal cells while promoting cell viability, implicating LXN in regulating proliferation and migration in endometrial tissue.\",\n      \"method\": \"LXN knockdown, Transwell migration assay, MTT cell viability assay\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, KD with phenotypic readout but no pathway placement\",\n      \"pmids\": [\"39202445\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LXN (Latexin) is the only known metallocarboxypeptidase inhibitor in humans and functions as a context-dependent regulator of stem cell proliferation, immune cell polarization, and vascular homeostasis: it physically interacts with Filamin A to regulate cytoskeletal remodeling in endothelial cells, inhibits JAK1/STAT3 signaling to suppress macrophage M2 polarization and PD-L2-mediated immune escape, is secreted via macrophage exosomes to inhibit Treg differentiation, activates the LXN/Rps3/p53 senescence pathway in renal epithelial cells, promotes intestinal stem cell proliferation via YAP/Wnt signaling, and in vascular smooth muscle cells controls PDGF receptor expression and ERK-dependent macrophage migration to regulate neointimal formation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n\n- [Retrieved 1] KEEP — canonical LXN protein in prostate cells\n- [Retrieved 2] KEEP — canonical LXN in macrophage/immune regulation\n- [Retrieved 3] KEEP — canonical LXN in endothelial cells\n- [Retrieved 4] EXCLUDE — case (B): circ_0002715/miR-127-5p circuit; LXN here is a downstream target in a circRNA study, not mechanistically characterized for LXN itself\n- [Retrieved 5] EXCLUDE — case (B): lncRNA DLEU2 study; LXN is a downstream readout, not mechanistically characterized\n- [Retrieved 6] KEEP — canonical LXN in endometrial/endometriosis context with functional assays\n- [Retrieved 7] KEEP — canonical LXN/Rps3/p53 signaling in renal epithelial cells\n- [Retrieved 8] KEEP — canonical LXN in intestinal stem cells\n- [Retrieved 9] KEEP — canonical LXN in macrophage exosomes/Treg regulation\n- [Retrieved 10] KEEP — canonical LXN-THBS2 axis in liver fibrosis\n- [Retrieved 11] KEEP (preprint) — canonical LXN in SMC/macrophage in neointima\n- [Retrieved 12] EXCLUDE — expression biomarker study (long COVID proteomics), no mechanistic LXN finding\n- [Retrieved 13] EXCLUDE — GWAS/MR study; LXN mentioned as association, no mechanism\n- [Curated 1] EXCLUDE — genome sequencing resource paper\n- [Curated 2] EXCLUDE — proteome-scale interactome map, no LXN-specific mechanism\n- [Curated 3] EXCLUDE — HuRI interactome map, no LXN-specific mechanism\n- [Curated 4] EXCLUDE — large-scale MS interactome, no LXN-specific mechanism\n- [Curated 5] EXCLUDE — census of protein complexes, no LXN-specific mechanism\n- [Curated 6] EXCLUDE — GO annotation methods paper\n- [Curated 7] EXCLUDE — MGC cDNA resource paper\n- [Curated 8] EXCLUDE — hORFeome resource paper\n- [Curated 9] EXCLUDE — podocyte exosome proteomics, LXN incidentally identified\n- [Curated 10] KEEP — crystal structure of LXN/hCPA4 complex, foundational mechanism\n- [Curated 11] KEEP — cloning and initial characterization of human LXN\n- [Curated 12] EXCLUDE — BAP1/NCoR1/γ-globin paper, no LXN content\n- [Curated 13] KEEP — LXN tumor suppressor in gastric cancer with functional assays\n- [Curated 14] KEEP — LXN in melanoma, stem cell transcription factor regulation\n- [Curated 15] KEEP — LXN/HECTD1/Rps3/NF-κB pathway in colitis\n- [Curated 16] KEEP — LXN regulates HSC niche proteins, proteomics\n- [Curated 17] KEEP — LXN cell cycle arrest via CDKIs in HCC\n- [Curated 18] EXCLUDE — PrPC interactome study; LXN incidental\n- [Curated 19] KEEP — LXN tumor suppressor in lymphoma, apoptosis mechanism\n- [Curated 20] KEEP — LXN secretion, retinoid/IFN signaling in prostate\n- [Curated 21] KEEP — LXN in thyroid cancer functional assays\n- [Curated 22] KEEP — LXN methylation and docetaxel resistance in prostate cancer\n- [Curated 23] KEEP — LXN apoptosis in CD133+ pancreatic CSCs\n- [Curated 24] KEEP — LXN apoptosis mechanism in pancreatic CSCs (Bcl-2/Bax/c-myc)\n- [Curated 25] EXCLUDE — SARS-CoV-2 hijackome; LXN incidental\n- [Curated 26] KEEP — review of LXN/Rps3/Thbs1 pathway in HSCs\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of human latexin (LXN) in complex with human carboxypeptidase A4 (hCPA4) revealed that LXN consists of two topologically equivalent subdomains structurally reminiscent of cystatins, each comprising an alpha-helix enveloped by a curved beta-sheet; the enzyme is bound at the interface of these subdomains. The complex occludes a large contact surface with relatively few contacts, explaining the nanomolar inhibition constant and the broad inhibitory spectrum across all vertebrate A/B metallocarboxypeptidases. Modeling studies explained why N/E subfamily MCPs and invertebrate A/B MCPs are not inhibited, due to differences in loop segments shaping the active-site access funnel.\",\n      \"method\": \"X-ray crystallography of LXN–hCPA4 complex; structural modeling for non-inhibited MCPs\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution crystal structure with mechanistic modeling; foundational structural paper\",\n      \"pmids\": [\"15738388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Human LXN encodes a 222-amino-acid protein with 84% sequence identity to rat and mouse latexin. Northern blot analysis demonstrated broad expression in 15 of 16 tissues examined (absent in peripheral blood leukocytes), with highest levels in heart, prostate, ovary, kidney, pancreas, and colon. The LXN gene spans ~5.9 kb, contains at least 6 exons, and maps to chromosome 3q25-q26.2.\",\n      \"method\": \"cDNA cloning from human fetal brain library; Northern blot analysis; genomic mapping\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct cloning and expression profiling; single lab, multiple methods\",\n      \"pmids\": [\"11455960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In human prostate epithelial cells, LXN localizes to the nucleus (distinct from RARRES1, which localizes to the endoplasmic reticulum). siRNA-mediated knockdown of LXN enhanced colony-forming ability (stem cell properties) and increased invasive capacity of primary prostate cultures. Inhibition of LXN fully rescued the anti-invasive effect induced by all-trans retinoic acid (atRA), establishing LXN as a downstream mediator of atRA's anti-invasion activity. LXN expression was co-ordinately repressed by DNA methylation in prostate cancer cell lines.\",\n      \"method\": \"siRNA knockdown; colony formation assay; invasion assay; subcellular localization by immunofluorescence; bisulfite methylation analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple orthogonal phenotypic readouts and localization data; single lab\",\n      \"pmids\": [\"23588494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Overexpression of LXN in LXN-negative gastric cancer cells (MGC803) inhibited colony formation and suppressed tumor growth in nude mice, while antisense-mediated knockdown in LXN-positive BGC823 cells enhanced tumor growth and colony formation. LXN overexpression differentially regulated tumor-related genes including Maspin, WFDC1, SLPI, S100P, and PDGFRB. CpG hypermethylation of the LXN promoter correlated with silenced LXN expression in cancer cell lines.\",\n      \"method\": \"Stable transfection (overexpression and antisense knockdown); colony formation assay; nude mouse xenograft; microarray gene expression; bisulfite sequencing\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with in vitro and in vivo readouts; single lab\",\n      \"pmids\": [\"21466706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Retrovirus-mediated overexpression of LXN in A20 mouse lymphoma cells inhibited in vitro growth ~16-fold and in vivo tumor volume ~2-fold. LXN-induced growth inhibition was associated with increased apoptosis and downregulation of anti-apoptotic genes Bcl-2 and Pim-2. Importantly, this tumor-suppressive mechanism was not dependent on LXN's canonical carboxypeptidase inhibitor activity.\",\n      \"method\": \"Retroviral overexpression; in vitro proliferation assay; mouse xenograft; RT-PCR for Bcl-2 and Pim-2; apoptosis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function in vitro and in vivo with defined molecular readouts; single lab\",\n      \"pmids\": [\"23028717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Proteomic analysis of Sca-1+ bone marrow cells from LXN-knockout mice demonstrated that latexin ablation reduced the abundance of multiple proteins involved in HSC niche interaction, including N-cadherin, Tie2, and Roundabout 4. LXN was found to co-localize with these niche molecules in hematopoietic stem/progenitor cells. LXN-deficient KSL cells showed enhanced self-renewal in methylcellulose colony assays, and LXN knockout increased KSL cell numbers in vivo.\",\n      \"method\": \"LXN-knockout mouse model; proteomics of Sca-1+ cells; immunofluorescence co-localization; methylcellulose colony assay; flow cytometry\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model with proteomics and functional colony assay; single lab\",\n      \"pmids\": [\"21567403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Exogenous LXN expression in melanoma cell lines significantly inhibited tumor cell proliferation and correlated with reduced expression of stem cell transcription factors OCT4, NANOG, SOX2, KLF4, and MYCN, suggesting LXN suppresses the stem cell-like properties of melanoma cells. The LXN CpG island promoter was hypermethylated in melanoma cell lines and tumors; 5-aza-2'-deoxycytidine treatment restored LXN expression.\",\n      \"method\": \"Exogenous LXN expression; proliferation assay; RT-PCR/Western blot for stem cell factors; bisulfite sequencing; demethylation drug treatment\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — gain-of-function with molecular readouts; single lab\",\n      \"pmids\": [\"23364479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LXN overexpression in hepatocellular carcinoma cells (SK-hep-1) promoted G0/G1 cell cycle arrest, while LXN silencing in YY-8103 cells promoted transition from G0/G1 to S phase. These effects were associated with differential expression of CDK inhibitors p21Cip1, p27Kip1, and p15INK4B, as well as cyclin D1 and cyclin E.\",\n      \"method\": \"LXN overexpression and shRNA knockdown; flow cytometry cell cycle analysis; Western blot for cell cycle regulators; colony formation; nude mouse xenograft\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with defined cell cycle molecular mechanism; single lab\",\n      \"pmids\": [\"24399246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LXN protein treatment of CD133+ MiaPaCa-2 pancreatic cancer stem-like cells increased apoptosis and inhibited proliferation in a dose-dependent manner, associated with downregulation of Bcl-2 and c-myc and upregulation of Bax.\",\n      \"method\": \"Exogenous LXN protein treatment; CCK-8 proliferation assay; flow cytometry apoptosis assay; Western blot for Bcl-2, Bax, c-myc\",\n      \"journal\": \"World journal of surgical oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct protein treatment with defined apoptotic molecular mechanism; single lab\",\n      \"pmids\": [\"25551472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LXN knockdown conferred docetaxel resistance to prostate cancer cells in vitro and in vivo, while LXN overexpression sensitized cells to docetaxel. Bone stromal cells decreased LXN expression through promoter methylation, inducing chemoresistance in co-cultured prostate cancer cells. In a mouse model, prostate cancer cells developed docetaxel resistance specifically in the bone microenvironment, coinciding with decreased LXN expression compared to the soft tissue microenvironment.\",\n      \"method\": \"siRNA knockdown; LXN overexpression; docetaxel resistance assays in vitro and in vivo; mouse xenograft; co-culture with bone stromal cells; bisulfite methylation analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain/loss-of-function with in vitro and in vivo validation; single lab\",\n      \"pmids\": [\"28087740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LXN protein is both cytosolic and secreted by normal prostate luminal cells. LXN overexpression in the luminal prostate cancer line LNCaP reduced plating efficiency. Transcriptome analysis showed LXN overexpression had significant indirect effects on genes involved in retinoid metabolism and IFN-associated inflammatory responses, without direct transcriptional effects, suggesting a post-transcriptional or signaling mechanism.\",\n      \"method\": \"LXN overexpression; colony/plating efficiency assay; transcriptome analysis (RNA-seq); Western blot; conditioned medium analysis for secretion\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — secretion demonstrated, transcriptome analysis reveals indirect pathway effects; single lab\",\n      \"pmids\": [\"30914656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LXN was identified as a suppressor of colitis. Proteomics revealed LXN physically interacts with HECTD1 (an E3 ubiquitin ligase) and ribosomal protein subunit Rps3, forming a functional complex. LXN expression promotes IκBα accumulation in intestinal epithelial cells; LXN knockdown enhances the HECTD1-Rps3 interaction, leading to ubiquitination and degradation of IκBα, and thereby activating NF-κB-driven inflammatory response. LXN deficiency aggravated DSS-induced colitis in mice.\",\n      \"method\": \"Proteomics/co-immunoprecipitation to identify LXN–HECTD1–Rps3 complex; Western blot for IκBα ubiquitination; LXN knockout mouse model (DSS colitis); ectopic LXN expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — complex identified by proteomics and Co-IP, ubiquitination mechanism established, validated in KO mouse model; multiple orthogonal methods\",\n      \"pmids\": [\"32555320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LXN interacts with Filamin A (FLNA) and regulates FLNA proteolytic cleavage and nuclear translocation in vascular endothelial cells. Laminar shear stress (LSS) reduces LXN expression in ECs; LXN knockdown recapitulates LSS-induced morphological changes and F-actin remodeling. LXN-/- and ApoE-/-LXN-/- double-knockout mice showed improved vascular permeability, vasodilation, and reduced atherosclerosis, establishing LXN as a regulator of endothelial morphology and vascular homeostasis.\",\n      \"method\": \"Co-immunoprecipitation (LXN–FLNA interaction); siRNA knockdown; F-actin imaging; LXN-/- and double-KO mouse models; vascular permeability and vasodilation assays; atherosclerosis assessment\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP interaction, KD phenotype with imaging, and in vivo KO model with multiple vascular endpoints; multiple orthogonal methods\",\n      \"pmids\": [\"34085389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LXN deficiency in macrophages promotes M2 polarization and upregulates PD-L2 expression (but not PD-L1), inhibiting T cell function in the tumor microenvironment. Mechanistically, LXN inhibits STAT3 transcriptional activity by targeting inhibition of JAK1 in macrophages. Adoptive transfer of wild-type macrophages rescued T cell function in LXN-deficient mice. Targeted inhibition of PD-L2 ameliorated cancer growth in LXN-deficient mice.\",\n      \"method\": \"LXN-knockout mouse model; subcutaneous tumor and AOM/DSS colorectal cancer models; flow cytometry for immune cell populations and polarization; co-culture macrophage-T cell systems; Western blot for JAK1/STAT3; adoptive macrophage transfer; PD-L2 inhibition\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse model with multiple tumor models, mechanistic pathway (JAK1/STAT3), adoptive transfer rescue; multiple orthogonal methods\",\n      \"pmids\": [\"36323670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN colocalizes with Lgr5+ intestinal stem cells (ISCs) in crypts. LXN deletion upregulates Lgr5 expression and enhances ISC proliferation, promoting intestinal organoid development. Mechanistically, LXN deficiency activates both the YAP and Wnt signaling pathways in ISCs, accelerating normal intestinal growth and regeneration post-injury.\",\n      \"method\": \"LXN-knockout mouse model; immunofluorescence co-localization with Lgr5; intestinal organoid culture; Western blot for YAP and Wnt pathway components; DSS-induced injury model\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model with organoid functional assay and pathway analysis; single lab\",\n      \"pmids\": [\"39208900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN is secreted by macrophages via exosomes. LXN-enriched macrophage-derived exosomes inhibit CD4+ T cell differentiation into Treg cells both in vitro and in vivo, enhancing tumor immune surveillance. Biomimetic nanoparticles loaded with LXN protein (MØ@LXN-NPS) recapitulated this Treg-inhibitory and anti-tumor activity.\",\n      \"method\": \"Macrophage-T cell co-culture system; exosome isolation and characterization; flow cytometry for Treg differentiation; in vivo tumor models; biomimetic nanoparticle engineering\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — exosomal secretion established, functional Treg inhibition shown in vitro and in vivo; single lab\",\n      \"pmids\": [\"39694381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LXN knockdown in endometrial stromal cells reduced their migratory capacity while promoting cell viability, indicating LXN positively regulates migration and negatively regulates proliferation in this cell type.\",\n      \"method\": \"LXN knockdown; Transwell migration assay; MTT viability assay\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, two functional assays without defined pathway mechanism\",\n      \"pmids\": [\"39202445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In renal tubular epithelial cells (RTECs), oxalate-induced oxidative stress activates the LXN/Rps3/p53 signaling pathway, promoting premature cellular senescence and SASP factor secretion, which in turn drives M1-like macrophage polarization and increased calcium oxalate crystal deposition. siRNA knockdown of LXN, or AAV-shLXN in a rat kidney stone model, reduced RTEC senescence, decreased SASP, reversed M1 macrophage polarization, and diminished intrarenal CaOx crystal deposition.\",\n      \"method\": \"siRNA knockdown of LXN; AAV-shLXN in rat model; SA-β-gal senescence staining; SASP cytokine measurement; macrophage co-culture; immunohistochemistry; Von Kossa staining\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway established with siRNA and in vivo AAV knockdown with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"41112268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LXN knockdown in mice (AAV9-shLXN) reduced CCl4-induced liver injury and suppressed hepatic stellate cell (HSC) activation, inhibiting α-SMA and collagen I expression. LXN expression showed a substantial positive correlation with THBS2 (thrombospondin-2), and LXN knockdown downregulated THBS2, suggesting LXN promotes liver fibrosis via a LXN-THBS2 signaling axis that drives HSC activation.\",\n      \"method\": \"AAV9-mediated LXN knockdown in mouse CCl4 liver fibrosis model; siLXN in LX-2 cells; qPCR; Western blot; immunohistochemistry; immunofluorescence\",\n      \"journal\": \"Frontiers in bioscience (Landmark edition)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro KD with defined molecular axis; single lab, correlation-supported mechanism\",\n      \"pmids\": [\"41761978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In smooth muscle cells (SMCs), LXN deficiency significantly attenuated SMC proliferation and migration by inhibiting PDGF receptor expression. In macrophages, LXN deficiency inhibited MCP-1-induced macrophage migration by suppressing ERK phosphorylation. Global, SMC-specific, and myeloid-specific LXN knockout (but not endothelial-specific KO) markedly prevented neointimal hyperplasia after carotid artery ligation in mice.\",\n      \"method\": \"Cell-type-specific LXN KO mouse models (global, SMC-specific, EC-specific, myeloid-specific); carotid artery ligation model; Western blot for PDGF receptors and ERK phosphorylation; immunofluorescence; proliferation and migration assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO models with defined molecular mechanisms; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.10.03.616555\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LXN acts endogenously in hematopoietic stem cells (HSCs) to negatively regulate their population size by enhancing apoptosis and decreasing self-renewal. LXN interacts with ribosomal protein Rps3 and inhibits its nuclear translocation, sensitizing hematopoietic cells to radiation-induced cell death. LXN inactivation downregulates thrombospondin 1 (Thbs1), connecting the LXN-Rps3 axis to downstream transcriptional effects.\",\n      \"method\": \"LXN knockout mouse model; repopulation assays; apoptosis assays; co-immunoprecipitation (LXN-Rps3); nuclear fractionation for Rps3 localization; radiation sensitivity assays (review summarizing primary experimental data)\",\n      \"journal\": \"Current opinion in hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing primary experimental findings (KO model, Co-IP, nuclear translocation) from the field; replicated across related studies\",\n      \"pmids\": [\"29608488\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LXN (latexin) is a secreted/cytosolic vertebrate metallocarboxypeptidase inhibitor whose crystal structure reveals it binds hCPA4 at the interface of two cystatin-like subdomains with nanomolar affinity; beyond this canonical enzymatic inhibitor role, LXN functions as a negative regulator of hematopoietic stem cell self-renewal and a tumor suppressor by forming a complex with HECTD1 and Rps3 to stabilize IκBα and suppress NF-κB signaling, inhibiting JAK1/STAT3 to prevent macrophage M2 polarization and PD-L2 upregulation, interacting with Filamin A to maintain endothelial cytoskeletal homeostasis, activating YAP/Wnt signaling in intestinal stem cells, driving a LXN/Rps3/p53 senescence axis in renal epithelial cells, and regulating SMC proliferation via PDGF receptor expression and macrophage migration via ERK phosphorylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LXN (Latexin) functions as a negative regulator of cell proliferation, migration, and immune polarization across multiple tissue contexts, acting through distinct signaling pathways in a cell-type-dependent manner. In macrophages, LXN inhibits JAK1/STAT3 signaling to suppress M2 polarization and PD-L2-mediated T cell suppression, and is secreted via exosomes to inhibit Treg differentiation, thereby promoting antitumor immunity [PMID:36323670, PMID:39694381]. In vascular cells, LXN physically interacts with Filamin A to regulate cytoskeletal remodeling in endothelial cells, controls PDGF receptor expression in smooth muscle cells, and modulates ERK-dependent macrophage migration to regulate neointimal formation [PMID:34085389]. LXN also activates the Rps3/p53 senescence pathway in renal epithelial cells under oxalate stress, and its deficiency in intestinal stem cells activates YAP/Wnt signaling to promote ISC proliferation [PMID:41112268, PMID:39208900].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing that LXN has a nuclear localization in epithelial cells and functions as a negative regulator of stem cell self-renewal and invasion answered whether LXN acts beyond its known role as a carboxypeptidase inhibitor.\",\n      \"evidence\": \"siRNA knockdown in primary prostate epithelial cultures with colony-forming and invasion assays, subcellular fractionation/imaging\",\n      \"pmids\": [\"23588494\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which nuclear LXN suppresses colony formation is unknown\",\n        \"Whether LXN's carboxypeptidase inhibitor activity contributes to these phenotypes was not tested\",\n        \"Limited to prostate epithelial cells; generalizability unclear\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying Filamin A as a direct physical interactant of LXN and showing that LXN regulates FLNA cleavage, nuclear translocation, and F-actin remodeling established a cytoskeletal mechanism through which LXN controls vascular permeability and atherosclerosis.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA knockdown in endothelial cells, LXN−/− and ApoE−/−LXN−/− double-knockout mouse models\",\n      \"pmids\": [\"34085389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether LXN directly cleaves FLNA or recruits a protease is unresolved\",\n        \"Structural basis of LXN–FLNA interaction is not determined\",\n        \"Whether FLNA interaction mediates LXN effects in non-vascular cell types is unknown\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that LXN inhibits JAK1/STAT3 signaling in macrophages and that LXN deficiency upregulates PD-L2 to suppress T cells revealed how LXN shapes the tumor immune microenvironment by controlling macrophage polarization and immune checkpoint expression.\",\n      \"evidence\": \"LXN-deficient mouse models, adoptive macrophage transfer, targeted PD-L2 inhibition, pathway analysis\",\n      \"pmids\": [\"36323670\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct binding target on JAK1 is not identified\",\n        \"Whether LXN's carboxypeptidase inhibition or a separate domain mediates JAK1 suppression is unknown\",\n        \"Relevance to human macrophage biology not validated\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Multiple 2024 studies expanded LXN's roles to intestinal stem cell regulation via YAP/Wnt, exosome-mediated Treg suppression, renal senescence via Rps3/p53, and cell-type-specific vascular remodeling, collectively establishing LXN as a pleiotropic negative regulator whose downstream pathway depends on cell type.\",\n      \"evidence\": \"LXN KO mice with intestinal organoids (YAP/Wnt); macrophage-derived exosome isolation with in vivo tumor models (Treg inhibition); cell-type-specific KO mice with carotid ligation (PDGF receptor/ERK); siRNA and AAV-shLXN in rat kidney stone model (Rps3/p53/senescence)\",\n      \"pmids\": [\"39208900\", \"39694381\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How LXN differentially activates YAP/Wnt versus JAK1/STAT3 versus Rps3/p53 in different cell types is mechanistically unresolved\",\n        \"The vascular cell-type-specific KO data remain in preprint form and await peer review\",\n        \"No structural or biochemical basis for pathway selectivity has been determined\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placing LXN upstream of Rps3/p53-mediated senescence in renal tubular epithelial cells under oxalate stress, with consequent SASP-driven M1 macrophage polarization, established a new context in which LXN promotes rather than inhibits inflammatory polarization.\",\n      \"evidence\": \"siRNA and AAV-shLXN in vivo knockdown, SA-β-gal staining, SASP measurement, macrophage polarization assay, rat kidney stone model\",\n      \"pmids\": [\"41112268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How LXN activates Rps3 is not biochemically defined\",\n        \"Whether LXN-induced senescence occurs in other epithelial tissues is untested\",\n        \"Apparent contradiction with LXN suppressing M2 polarization in tumor macrophages needs reconciliation\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying mechanism explaining how LXN engages distinct downstream pathways (JAK1/STAT3, YAP/Wnt, Rps3/p53, FLNA, PDGF receptor) in different cellular contexts remains unknown, and the contribution of LXN's carboxypeptidase inhibitor activity to any of these phenotypes has not been tested.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No crystal structure of LXN in complex with any signaling partner exists\",\n        \"Enzymatic inhibitor activity has not been separated from signaling functions\",\n        \"No human genetic studies linking LXN variants to disease phenotypes have been reported\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 5]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 5, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"FLNA\",\n      \"JAK1\",\n      \"RPS3\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Latexin (LXN) is a vertebrate-specific protein that functions both as a nanomolar-affinity inhibitor of A/B metallocarboxypeptidases and as a pleiotropic regulator of cell proliferation, apoptosis, and inflammatory signaling in diverse tissue contexts. Structurally, LXN comprises two cystatin-like subdomains that bind the active-site funnel of carboxypeptidase A4, occluding a large contact surface to achieve broad-spectrum inhibition of vertebrate metallocarboxypeptidases [PMID:15738388]. Independent of its carboxypeptidase-inhibitory activity, LXN negatively regulates hematopoietic stem cell self-renewal and promotes apoptosis through interaction with ribosomal protein Rps3 and inhibition of its nuclear translocation [PMID:29608488, PMID:23028717]; in intestinal epithelial cells, LXN forms a complex with the E3 ubiquitin ligase HECTD1 and Rps3 to stabilize IκBα and suppress NF-κB-driven inflammation [PMID:32555320], while in macrophages it restrains M2 polarization and PD-L2 expression by inhibiting JAK1/STAT3 signaling [PMID:36323670]. LXN is frequently silenced by promoter CpG hypermethylation across gastric, prostate, melanoma, and hepatocellular cancers, and its re-expression suppresses tumor growth, induces G0/G1 arrest, and sensitizes cancer cells to chemotherapy [PMID:21466706, PMID:24399246, PMID:28087740].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Cloning of human LXN established it as a broadly expressed gene mapping to 3q25-q26.2, setting the stage for functional studies beyond the original rat brain context.\",\n      \"evidence\": \"cDNA cloning from human fetal brain library; Northern blot across 16 tissues; genomic mapping\",\n      \"pmids\": [\"11455960\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional assay performed in this study\",\n        \"Protein-level expression across tissues not assessed\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Determination of the LXN–hCPA4 crystal structure resolved the molecular basis of metallocarboxypeptidase inhibition, revealing two cystatin-like subdomains that clamp the enzyme's active-site funnel with nanomolar affinity and explaining why invertebrate and N/E-subfamily MCPs escape inhibition.\",\n      \"evidence\": \"X-ray crystallography of LXN–hCPA4 complex; structural modeling of non-inhibited MCPs\",\n      \"pmids\": [\"15738388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"No mutagenesis to validate key contact residues\",\n        \"Kinetic parameters for inhibition of individual MCP family members not systematically measured\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reciprocal gain- and loss-of-function experiments in gastric cancer demonstrated that LXN acts as a tumor suppressor whose promoter is silenced by CpG methylation, linking epigenetic regulation to its growth-inhibitory role.\",\n      \"evidence\": \"Stable overexpression and antisense knockdown in gastric cancer cells; nude mouse xenograft; bisulfite sequencing\",\n      \"pmids\": [\"21466706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Downstream targets (Maspin, PDGFRB, etc.) identified by microarray but not validated by loss-of-function\",\n        \"Methylation-growth relationship is correlative, no demethylation rescue in vivo\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Studies in hematopoietic stem cells and lymphoma cells established that LXN restricts HSC self-renewal and induces apoptosis through a mechanism independent of its carboxypeptidase-inhibitory activity, broadening its functional repertoire beyond enzyme inhibition.\",\n      \"evidence\": \"LXN-KO mouse HSC colony assays and proteomics; retroviral LXN overexpression in A20 lymphoma cells with apoptosis and xenograft readouts\",\n      \"pmids\": [\"21567403\", \"23028717\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The carboxypeptidase-independent mechanism was not molecularly defined at this stage\",\n        \"Downstream apoptotic targets (Bcl-2, Pim-2) not validated by rescue experiments\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Nuclear localization of LXN in prostate epithelial cells and its role as a mediator of retinoic acid–induced invasion suppression revealed a compartment-specific tumor-suppressive function distinct from its cytosolic enzymatic role.\",\n      \"evidence\": \"siRNA knockdown; invasion and colony-formation assays; immunofluorescence localization; bisulfite methylation analysis in prostate cells\",\n      \"pmids\": [\"23588494\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Nuclear binding partners not identified\",\n        \"Mechanism linking nuclear LXN to retinoic acid signaling pathway not defined\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of LXN-regulated cell cycle arrest via CDK inhibitors (p21, p27, p15) and cyclin D1/E in hepatocellular carcinoma provided a concrete proliferative checkpoint mechanism for its tumor-suppressive activity.\",\n      \"evidence\": \"LXN overexpression and shRNA knockdown in HCC lines; flow cytometry cell cycle analysis; Western blot for CDK inhibitors\",\n      \"pmids\": [\"24399246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct versus indirect regulation of CDK inhibitors not distinguished\",\n        \"No epistasis experiment to confirm CDK inhibitors are required for LXN-mediated arrest\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The discovery that LXN binds Rps3 and inhibits its nuclear translocation provided the first defined signaling partner for LXN's carboxypeptidase-independent functions in HSC regulation and radiation sensitivity.\",\n      \"evidence\": \"Co-immunoprecipitation of LXN–Rps3; nuclear fractionation; LXN-KO mouse repopulation and radiation sensitivity assays\",\n      \"pmids\": [\"29608488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Primary data cited from review; structural basis of LXN–Rps3 interaction unknown\",\n        \"Downstream transcriptional targets of nuclear Rps3 in HSCs not comprehensively defined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of the LXN–HECTD1–Rps3 complex and its role in stabilizing IκBα to suppress NF-κB provided a defined ubiquitin-dependent mechanism through which LXN restrains intestinal inflammation.\",\n      \"evidence\": \"Proteomics and Co-IP for LXN–HECTD1–Rps3 complex; IκBα ubiquitination assays; LXN-KO mouse DSS colitis model\",\n      \"pmids\": [\"32555320\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether LXN competes with Rps3 for HECTD1 binding or allosterically modulates the complex is unresolved\",\n        \"No structural model of the ternary complex\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that LXN interacts with Filamin A and regulates its cleavage and nuclear translocation extended LXN's mechanistic scope to cytoskeletal and vascular homeostasis, with LXN deletion protecting against atherosclerosis.\",\n      \"evidence\": \"Co-IP of LXN–FLNA; siRNA knockdown with F-actin imaging; LXN−/− and ApoE−/−LXN−/− double-KO mice with vascular permeability, vasodilation, and atherosclerosis endpoints\",\n      \"pmids\": [\"34085389\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Binding domain on FLNA not mapped\",\n        \"Mechanism by which LXN regulates FLNA proteolytic cleavage not identified\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstration that LXN inhibits JAK1/STAT3 signaling in macrophages to prevent M2 polarization and PD-L2 upregulation established LXN as a checkpoint in anti-tumor immunity, rescued by adoptive transfer of WT macrophages.\",\n      \"evidence\": \"LXN-KO mouse tumor models; macrophage–T cell co-culture; Western blot for JAK1/STAT3; adoptive macrophage transfer; PD-L2 blockade\",\n      \"pmids\": [\"36323670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct physical interaction between LXN and JAK1 not demonstrated\",\n        \"Mechanism of selective PD-L2 (not PD-L1) regulation unclear\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Multiple 2024 studies revealed additional LXN functions: activation of YAP/Wnt in intestinal stem cells upon LXN loss, exosomal LXN secretion by macrophages that inhibits Treg differentiation, and context-dependent roles in endometrial stromal cell migration.\",\n      \"evidence\": \"LXN-KO mouse intestinal organoids with YAP/Wnt pathway analysis; exosome isolation from macrophages with Treg co-culture; LXN knockdown in endometrial stromal cells\",\n      \"pmids\": [\"39208900\", \"39694381\", \"39202445\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"YAP and Wnt activation mechanism (direct target vs. indirect) not resolved\",\n        \"Exosomal LXN cargo sorting mechanism unknown\",\n        \"Endometrial migration finding lacks pathway-level mechanism\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The LXN/Rps3/p53 axis was implicated in oxidative stress–induced cellular senescence in renal tubular cells, linking LXN to SASP-driven macrophage polarization and kidney stone pathogenesis.\",\n      \"evidence\": \"siRNA and AAV-shLXN knockdown in rat kidney stone model; SA-β-gal senescence staining; SASP cytokine measurement; macrophage co-culture\",\n      \"pmids\": [\"41112268\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How LXN activates p53 is not defined\",\n        \"Whether the Rps3 interaction mediates p53 stabilization or transcriptional activation is untested\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of LXN's interactions with Rps3, HECTD1, and FLNA; how a single protein integrates carboxypeptidase inhibition with NF-κB, JAK/STAT, YAP/Wnt, and p53 signaling; and whether these diverse functions are executed by distinct LXN pools (nuclear, cytosolic, secreted/exosomal).\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structure of LXN in complex with any non-MCP partner\",\n        \"Compartment-specific functions not systematically dissected with domain mutants\",\n        \"Relative contribution of carboxypeptidase-dependent vs -independent mechanisms to in vivo phenotypes untested\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 4, 13]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 12]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [10, 15]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 13, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 13, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 8, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 7, 9]}\n    ],\n    \"complexes\": [\n      \"LXN-HECTD1-Rps3\"\n    ],\n    \"partners\": [\n      \"CPA4\",\n      \"RPS3\",\n      \"HECTD1\",\n      \"FLNA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}